News

The phase 3 trial, called ECLIPSE, enrolled 1048 patients to evaluate the efficacy and safety of Tremfya in comparison to Cosentyx. While Tremfya is an interleukin (IL)-23-targeted biologic

The joint team is focused on the discovery of efficacious inhibitors of PknB, which is essential for the growth of Mycobacterium tuberculosis (TB). Schrödinger’s computational platform has led

Zilucoplan, which is a synthetic, macrocyclic peptide, achieved clinically meaningful and statistically significant reductions across the primary and key secondary endpoints for its two dose groups in comparison

Black Diamond is the first company launched out of Ridgeline, Versant’s Discovery Engine based in Basel, Switzerland, and has a unique platform capable of prosecuting allosteric mutant oncogenes.

Circassia has issued a notice of option exercise to AstraZeneca related to US commercial rights of Tudorza. The company intends to complete the option exercise by the end

The agreement allows both firms to resolve all litigation across the world. It will enable Alnylam to reduce the costs and distraction linked with continued litigation in various

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts

The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,